Admin hitch delays US verdict for GSK H5N1 vaccine
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline said it received a complete response letter from the FDA for the London firm's Q-Pan H5N1 pandemic influenza A virus monovalent adjuvanted vaccine – declaring the action was not triggered by a safety or efficacy concern but was due to an administrative hitch.